Annual report
6545.TEDINET S100QW4N
Period2022-04-01 → 2023-03-31
Filed2023-06-28
StandardJapan GAAP
ConsolidatedYes
Data checks23 of 23 passed
Key figures · 120
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥4.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥4.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Operating income | ¥99m | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Operating income | ¥156m | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | ¥149m | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥290m | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Profit before tax | ¥107m | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥287m | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥35m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥186m | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥35m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Net income | ¥186m | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥3.2bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥2.8bn | at 2022-03-31 | Cons. | Assets |
| Total liabilities | ¥1.9bn | at 2023-03-31 | Cons. | Liabilities |
| Total liabilities | ¥1.6bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥1.3bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥1.2bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥1.0bn | at 2021-03-31d | Cons. | Net assets |
| Cash and deposits | ¥1.1bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.1bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.1bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.1bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥845m | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥303m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥272m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥302m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥236m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥24m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥250m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥6.5 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥34.67 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥6.36 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥33.74 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥238.79 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥231.64 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 40.5% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 44.0% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 2.8% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 15.0% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| Employees | 374 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 329 | at 2022-03-31 | Cons. | Number of employees |
| Revenue | ¥2.1bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥3.5bn | 2021-04-01 → 2022-03-31 | Standalone | Net sales |
| Revenue | ¥3.5bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥3.6bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥3.4bn | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | −¥165m | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | ¥148m | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | −¥7m | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥281m | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥250m | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥216m | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥104m | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥49m | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥278m | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | −¥31m | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥187m | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥150m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥122m | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥65m | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥2.7bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥2.7bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥2.3bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥2.5bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.9bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥1.5bn | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥1.5bn | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥1.2bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥1.2bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥1.0bn | at 2021-03-31d | Standalone | Net assets |
| Net assets / equity | ¥853m | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥816m | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥696m | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.0bn | at 2022-03-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥845m | at 2021-03-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥930m | at 2020-03-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥430m | at 2019-03-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥362m | 2020-04-01 → 2021-03-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥395m | 2019-04-01 → 2020-03-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥154m | 2018-04-01 → 2019-03-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥104m | 2020-04-01 → 2021-03-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥170m | 2019-04-01 → 2020-03-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥168m | 2018-04-01 → 2019-03-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥343m | 2020-04-01 → 2021-03-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥275m | 2019-04-01 → 2020-03-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥39m | 2018-04-01 → 2019-03-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-5.66 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥34.85 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥28.08 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥22.96 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥12.12 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥33.91 | 2021-04-01 → 2022-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥27.29 | 2020-04-01 → 2021-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥22.21 | 2019-04-01 → 2020-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥11.64 | 2018-04-01 → 2019-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥222.67 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥232.38 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥190.07 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥160.09 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥150.79 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 45.2% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 46.0% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 43.4% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.7% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 42.8% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 16.5% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 16.1% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 14.7% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.7% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 5,427,771 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 5,427,771 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 5,427,771 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 5,427,771 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 5,413,371 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 202 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 296 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 319 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 301 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 292 | at 2019-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 33
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | depreciation | 2022-04-01 → 2023-03-31 | ¥6m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥603m |
| Health Care Solution Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥113m |
| Health Care Solution Businessreportable segment | employees | at 2023-03-31 | 237 pure |
| Health Care Solution Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥3.1bn |
| Health Care Solution Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥3.1bn |
| Health Care Solution Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥418m |
| Home Care Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥8m |
| Home Care Businessreportable segment | employees | at 2023-03-31 | 108 pure |
| Home Care Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥1.3bn |
| Home Care Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥1.3bn |
| Home Care Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥285m |
| —segment total | depreciation | 2022-04-01 → 2023-03-31 | ¥121m |
| —segment total | employees | at 2023-03-31 | 345 pure |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥4.5bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥4.5bn |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥703m |
| Reconciling Itemsreconciling | depreciation | 2021-04-01 → 2022-03-31 | ¥4m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | −¥560m |
| Health Care Solution Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥121m |
| Health Care Solution Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥2.9bn |
| Health Care Solution Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥2.9bn |
| Health Care Solution Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥338m |
| Home Care Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥7m |
| Home Care Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥1.3bn |
| Home Care Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥1.3bn |
| Home Care Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥378m |
| —segment total | depreciation | 2021-04-01 → 2022-03-31 | ¥128m |
| —segment total | revenue | 2021-04-01 → 2022-03-31 | ¥4.2bn |
| —segment total | revenue external | 2021-04-01 → 2022-03-31 | ¥4.2bn |
| —segment total | segment profit | 2021-04-01 → 2022-03-31 | ¥716m |
| Health Care Solution Businessreportable segment | employees | at 2023-03-31 | 173 pure |
| —segment total | employees | at 2023-03-31 | 173 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,278
| Item | Context | Value | Unit |
|---|---|---|---|
| Long term loans payable | CurrentYearInstant | 307780000 | JPY |
| Asset retirement obligations ncl | Prior1YearInstant | 48898000 | JPY |
| Asset retirement obligations ncl | CurrentYearInstant | 64159000 | JPY |
| Long term unearned revenue | Prior1YearInstant | 20470000 | JPY |
| Long term unearned revenue | CurrentYearInstant | 16647000 | JPY |
| Other ncl | Prior1YearInstant | 50361000 | JPY |
| Other ncl | CurrentYearInstant | 50777000 | JPY |
| Noncurrent liabilities | Prior1YearInstant | 463513000 | JPY |
| Noncurrent liabilities | CurrentYearInstant | 439364000 | JPY |
| Liabilities | Prior1YearInstant | 1584009000 | JPY |
| Liabilities | CurrentYearInstant | 1896206000 | JPY |
| Capital stock | Prior1YearInstant | 252302000 | JPY |
| Capital stock | CurrentYearInstant | 252302000 | JPY |
| Capital surplus | Prior1YearInstant | 237302000 | JPY |
| Capital surplus | CurrentYearInstant | 237302000 | JPY |
| Retained earnings | Prior1YearInstant | 798308000 | JPY |
| Retained earnings | CurrentYearInstant | 822945000 | JPY |
| Treasury stock | Prior1YearInstant | -42615000 | JPY |
| Treasury stock | CurrentYearInstant | -23183000 | JPY |
| Shareholders equity | Prior1YearInstant | 1245297000 | JPY |
| Shareholders equity | CurrentYearInstant | 1289367000 | JPY |
| Valuation difference on available for sale securities | Prior1YearInstant | － | JPY |
| Valuation difference on available for sale securities | CurrentYearInstant | -5000 | JPY |
| Valuation and translation adjustments | Prior1YearInstant | － | JPY |
| Valuation and translation adjustments | CurrentYearInstant | -5000 | JPY |
| Net assets | Prior1YearInstant | 1245297000 | JPY |
| Net assets | CurrentYearInstant | 1289361000 | JPY |
| Liabilities and net assets | Prior1YearInstant | 2829307000 | JPY |
| Liabilities and net assets | CurrentYearInstant | 3185568000 | JPY |
| Net sales | Prior1YearDuration | 4168077000 | JPY |
| Net sales | CurrentYearDuration | 4464419000 | JPY |
| Cost of sales | Prior1YearDuration | 2700154000 | JPY |
| Cost of sales | CurrentYearDuration | 2815214000 | JPY |
| Gross profit | Prior1YearDuration | 1467923000 | JPY |
| Gross profit | CurrentYearDuration | 1649204000 | JPY |
| Selling general and administrative expenses | Prior1YearDuration | 1311867000 | JPY |
| Selling general and administrative expenses | CurrentYearDuration | 1550170000 | JPY |
| Operating income | Prior1YearDuration | 156055000 | JPY |
| Operating income | CurrentYearDuration | 99033000 | JPY |
| Gain on transfer of business noi | Prior1YearDuration | 32246000 | JPY |
| Gain on transfer of business noi | CurrentYearDuration | 21838000 | JPY |
| Subsidy income noi bounty | Prior1YearDuration | 109120000 | JPY |
| Subsidy income noi bounty | CurrentYearDuration | 32742000 | JPY |
| Other noi | Prior1YearDuration | 7095000 | JPY |
| Other noi | CurrentYearDuration | 20346000 | JPY |
| Non operating income | Prior1YearDuration | 148462000 | JPY |
| Non operating income | CurrentYearDuration | 74928000 | JPY |
| Interest expenses noe | Prior1YearDuration | 14187000 | JPY |
| Interest expenses noe | CurrentYearDuration | 15961000 | JPY |
| Office transfer expenses noe | Prior1YearDuration | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 23 of 23 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |